Evaluation of the factor V HR2 haplotype as a risk factor for ischemic cerebrovascular disease

Haematologica

Volumn 88, Issue 2, 2003, Pages 236-237

  Lecumberri, Ramon ^a   Ceberio, Izaskun ^a   Montes, Ramon ^a   Lopez, Maria Luz ^b   Alberca, Ignacio ^b   Rocha, Eduardo ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

APCR; Cerebrovascular disease; HR2 haplotype

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; GENE PRODUCT;

ACTIVATED PROTEIN C RESISTANCE; ARTICLE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENE HR2; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; PATHOGENESIS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; ADULT; BRAIN ISCHEMIA; CASE CONTROL STUDY; FEMALE; GENETICS; LETTER; MALE; MIDDLE AGED; STATISTICAL ANALYSIS;

ADULT; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; CEREBROVASCULAR DISORDERS; DATA INTERPRETATION, STATISTICAL; FACTOR V; FEMALE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 0037946750     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996;125:265-9.
2. Juul K, Tybjaerg-Hansen A, Steffensen R, Kofoed S, Jensen G, Nordestgaard BG. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood 2002;100:3-10.
3. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90:1552-7.
4. de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000;83:577-82.
5. Castoldi E, Rosing J, Girelli D, Hoekema L, Lunghi B, Mingozzi F, et al. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000;83:362-5.
6. Koeleman BP, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994;84:1031-5.
7. Lunghi B, Iacovello L, Gemmati D, Dilasio MG, Castoldi E, Pinotti M, et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996;75:45-8.
8. Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 2002;99:2720-5.
9. Doggen CJM, de Visser MCH, Vos HL, Bertina RM, Cats VM, Rosendaal FR. The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. Thromb Haemost 2000;84:815-8.